American Shared Hospital Services Q1 2026 Earnings Insights
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 2 days ago
0mins
Should l Buy AMS?
Source: seekingalpha
- Leadership Transition: In late April, the company announced CEO Gary Delanois's resignation for personal reasons, with Craig Tagawa appointed as Interim CEO, which may influence the company's strategic direction and execution capabilities.
- Significant Revenue Growth: Q1 2026 total revenue increased by 15.9% year-over-year to $7.1 million, surpassing analysts' estimates of $6.87 million, indicating strong contributions from Rhode Island and Puebla radiation therapy centers, thus enhancing the company's competitive position in the market.
- International Market Opportunities: Management highlighted the expected operational launch of the Guadalajara Center later this year, reflecting the company's focus on international market expansion, which could provide new revenue growth drivers in the future.
- Improved Cash Flow Position: By the end of the quarter, the company reported cash and cash equivalents of $5.2 million, a significant increase from $3.7 million at year-end, indicating improved financial health in operations and enhancing flexibility for future investments and expansions.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy AMS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on AMS
About AMS
American Shared Hospital Services is a provider of turn-key technology solutions for stereotactic radiosurgery and advanced radiation therapy equipment and services. Its segments include Leasing and Retail. The Leasing segment comprises the Company’s medical equipment leasing. The Retail segment comprises facilities in Peru and Ecuador. Its Proton Beam Radiation Therapy Operations is an alternative to traditional external beam, photon-based radiation delivered by linear accelerators. Its Gamma Knife stereotactic radiosurgery, a non-invasive procedure, is an alternative to conventional brain surgery and/or radiation therapy. The Gamma Knife treats selected malignant and benign brain tumors, arteriovenous malformations, and functional disorders including trigeminal neuralgia (facial pain). It can be an adjunct to conventional brain surgery, radiation therapy, or chemotherapy. The Company provides radiation therapy services both domestically and internationally.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
American Shared Hospital Services Q1 2026 Earnings Insights
- Leadership Transition: In late April, the company announced CEO Gary Delanois's resignation for personal reasons, with Craig Tagawa appointed as Interim CEO, which may influence the company's strategic direction and execution capabilities.
- Significant Revenue Growth: Q1 2026 total revenue increased by 15.9% year-over-year to $7.1 million, surpassing analysts' estimates of $6.87 million, indicating strong contributions from Rhode Island and Puebla radiation therapy centers, thus enhancing the company's competitive position in the market.
- International Market Opportunities: Management highlighted the expected operational launch of the Guadalajara Center later this year, reflecting the company's focus on international market expansion, which could provide new revenue growth drivers in the future.
- Improved Cash Flow Position: By the end of the quarter, the company reported cash and cash equivalents of $5.2 million, a significant increase from $3.7 million at year-end, indicating improved financial health in operations and enhancing flexibility for future investments and expansions.
See More
American Shared Hospital Q1 Earnings Report
- Earnings Highlights: American Shared Hospital reported a Q1 GAAP EPS of -$0.09, indicating a loss; however, revenue increased by 15.9% year-over-year to $7.1 million, demonstrating the company's resilience and growth potential in the market.
- Adjusted EBITDA Growth: The adjusted EBITDA rose to $1.1 million from $0.9 million in the prior year quarter, reflecting an 18.4% increase that indicates significant progress in cost control and operational efficiency.
- Improved Cash Position: As of March 31, 2026, the company had cash, cash equivalents, and restricted cash totaling $5.2 million, a substantial increase from $3.7 million at December 31, 2025, enhancing the company's financial stability and capacity for future investments.
- Future Development Plans: The company is set to launch its Bristol facility in late 2027 and plans to establish a Rhode Island proton center in 2028, showcasing its long-term strategic positioning and intent to expand in the healthcare services sector.
See More
Sand Grove Capital Management Discloses Shareholding Information
- Shareholding Disclosure: Sand Grove Capital Management disclosed its stake in Advanced Medical Solutions Group plc on May 12, 2026, revealing ownership of 2,184,661 ordinary shares, representing 0.99%, indicating its investment intentions in the company.
- Derivatives Position: The firm also holds 851,483 cash-settled derivatives, with total positions in relevant securities reaching 3,036,144 shares, or 1.38%, showcasing its active trading strategy in the market.
- Trading Activity Overview: Recently, Sand Grove purchased 179,888 ordinary shares at a price of 246 pence, reflecting its bullish outlook on the stock and increasing its holdings.
- Compliance Information: This disclosure adheres to Rule 8 of the Takeover Code, ensuring transparency and maintaining market fairness, highlighting Sand Grove's commitment to compliance.
See More
Amadeus IT Group Reports Strong Earnings Growth Amid Challenges
- Revenue Growth: Amadeus IT Group reported revenue of EUR 1.683 billion, reflecting an 8% growth at constant currency, demonstrating the company's resilience despite geopolitical disruptions, although foreign exchange effects have moderated overall growth.
- Adjusted EBIT and EPS: The adjusted EBIT reached EUR 500 million, a 7% increase, while adjusted diluted EPS stood at EUR 0.83, growing by 9%, indicating effective strategies in enhancing profitability amidst challenging conditions.
- R&D Investment and AI Development: The company invested EUR 335 million in R&D, accounting for 20% of revenue, despite a 6.1% decline from the previous year; notably, 50% of capital expenditures are directed towards product and solution development to enhance AI capabilities and market competitiveness.
- Acquisition Plans and Market Challenges: Amadeus intends to acquire Idemia Public Security to bolster its biometrics technology platform, although it faces challenges from geopolitical uncertainties in the Middle East that are expected to temper booking growth in Q2, impacting overall performance outlook.
See More
Rathbones Group Discloses Shareholding Information
- Shareholding Disclosure: Rathbones Group disclosed its shareholding in Advanced Medical Solutions Group plc on April 22, 2026, holding 14,390,925 ordinary shares, representing 6.55% of the relevant securities, complying with Rule 8.3 of the Takeover Code to ensure market transparency.
- Trading Activity Overview: The latest disclosure includes multiple stock transactions, selling 1,770 shares, 3,856 shares, 2,710 shares, and 941 shares at prices of 260.692 pence, 258.661 pence, 257.50 pence, and 257.38 pence respectively, indicating active market participation.
- Compliance and Transparency: This disclosure aligns with the requirements of the Takeover Code, enhancing investor trust in Rathbones' compliance and transparency, which may positively impact its stock price stability.
- Market Reaction Expectations: Although this disclosure does not involve significant transactions or changes, the transparent shareholding information may influence market confidence in Rathbones, especially in the context of investor focus on corporate governance and compliance.
See More
AMS Reports Revenue Decline but Improved Losses in Q4 2025
- Revenue Decline: Total revenue for Q4 2025 was $7.7 million, a 14.8% decrease year-over-year, primarily due to the expiration of three Gamma Knife contracts and reduced proton radiation therapy volumes, highlighting the company's vulnerability in revenue diversification.
- Growth in Direct Patient Care Services: Revenue from direct patient care services reached $4.8 million, accounting for 63% of total revenue and reflecting a 2.6% year-over-year increase, indicating stability and long-term growth potential in this segment.
- Significant Gross Margin Decline: The gross margin for Q4 dropped to 12%, down from 35% in the previous year, illustrating the negative impact of reduced treatment volumes and a shift in revenue mix on profitability.
- Improved Net Loss: The net loss for Q4 was $631,000, an improvement from a net loss of $1.6 million in the same quarter last year, yet it still presents challenges for the company's recovery in profitability.
See More
American Shared Hospital Services Q1 2026 Earnings Insights
- Leadership Transition: In late April, the company announced CEO Gary Delanois's resignation for personal reasons, with Craig Tagawa appointed as Interim CEO, which may influence the company's strategic direction and execution capabilities.
- Significant Revenue Growth: Q1 2026 total revenue increased by 15.9% year-over-year to $7.1 million, surpassing analysts' estimates of $6.87 million, indicating strong contributions from Rhode Island and Puebla radiation therapy centers, thus enhancing the company's competitive position in the market.
- International Market Opportunities: Management highlighted the expected operational launch of the Guadalajara Center later this year, reflecting the company's focus on international market expansion, which could provide new revenue growth drivers in the future.
- Improved Cash Flow Position: By the end of the quarter, the company reported cash and cash equivalents of $5.2 million, a significant increase from $3.7 million at year-end, indicating improved financial health in operations and enhancing flexibility for future investments and expansions.
See More
American Shared Hospital Q1 Earnings Report
- Earnings Highlights: American Shared Hospital reported a Q1 GAAP EPS of -$0.09, indicating a loss; however, revenue increased by 15.9% year-over-year to $7.1 million, demonstrating the company's resilience and growth potential in the market.
- Adjusted EBITDA Growth: The adjusted EBITDA rose to $1.1 million from $0.9 million in the prior year quarter, reflecting an 18.4% increase that indicates significant progress in cost control and operational efficiency.
- Improved Cash Position: As of March 31, 2026, the company had cash, cash equivalents, and restricted cash totaling $5.2 million, a substantial increase from $3.7 million at December 31, 2025, enhancing the company's financial stability and capacity for future investments.
- Future Development Plans: The company is set to launch its Bristol facility in late 2027 and plans to establish a Rhode Island proton center in 2028, showcasing its long-term strategic positioning and intent to expand in the healthcare services sector.
See More
Sand Grove Capital Management Discloses Shareholding Information
- Shareholding Disclosure: Sand Grove Capital Management disclosed its stake in Advanced Medical Solutions Group plc on May 12, 2026, revealing ownership of 2,184,661 ordinary shares, representing 0.99%, indicating its investment intentions in the company.
- Derivatives Position: The firm also holds 851,483 cash-settled derivatives, with total positions in relevant securities reaching 3,036,144 shares, or 1.38%, showcasing its active trading strategy in the market.
- Trading Activity Overview: Recently, Sand Grove purchased 179,888 ordinary shares at a price of 246 pence, reflecting its bullish outlook on the stock and increasing its holdings.
- Compliance Information: This disclosure adheres to Rule 8 of the Takeover Code, ensuring transparency and maintaining market fairness, highlighting Sand Grove's commitment to compliance.
See More
Amadeus IT Group Reports Strong Earnings Growth Amid Challenges
- Revenue Growth: Amadeus IT Group reported revenue of EUR 1.683 billion, reflecting an 8% growth at constant currency, demonstrating the company's resilience despite geopolitical disruptions, although foreign exchange effects have moderated overall growth.
- Adjusted EBIT and EPS: The adjusted EBIT reached EUR 500 million, a 7% increase, while adjusted diluted EPS stood at EUR 0.83, growing by 9%, indicating effective strategies in enhancing profitability amidst challenging conditions.
- R&D Investment and AI Development: The company invested EUR 335 million in R&D, accounting for 20% of revenue, despite a 6.1% decline from the previous year; notably, 50% of capital expenditures are directed towards product and solution development to enhance AI capabilities and market competitiveness.
- Acquisition Plans and Market Challenges: Amadeus intends to acquire Idemia Public Security to bolster its biometrics technology platform, although it faces challenges from geopolitical uncertainties in the Middle East that are expected to temper booking growth in Q2, impacting overall performance outlook.
See More
Rathbones Group Discloses Shareholding Information
- Shareholding Disclosure: Rathbones Group disclosed its shareholding in Advanced Medical Solutions Group plc on April 22, 2026, holding 14,390,925 ordinary shares, representing 6.55% of the relevant securities, complying with Rule 8.3 of the Takeover Code to ensure market transparency.
- Trading Activity Overview: The latest disclosure includes multiple stock transactions, selling 1,770 shares, 3,856 shares, 2,710 shares, and 941 shares at prices of 260.692 pence, 258.661 pence, 257.50 pence, and 257.38 pence respectively, indicating active market participation.
- Compliance and Transparency: This disclosure aligns with the requirements of the Takeover Code, enhancing investor trust in Rathbones' compliance and transparency, which may positively impact its stock price stability.
- Market Reaction Expectations: Although this disclosure does not involve significant transactions or changes, the transparent shareholding information may influence market confidence in Rathbones, especially in the context of investor focus on corporate governance and compliance.
See More
AMS Reports Revenue Decline but Improved Losses in Q4 2025
- Revenue Decline: Total revenue for Q4 2025 was $7.7 million, a 14.8% decrease year-over-year, primarily due to the expiration of three Gamma Knife contracts and reduced proton radiation therapy volumes, highlighting the company's vulnerability in revenue diversification.
- Growth in Direct Patient Care Services: Revenue from direct patient care services reached $4.8 million, accounting for 63% of total revenue and reflecting a 2.6% year-over-year increase, indicating stability and long-term growth potential in this segment.
- Significant Gross Margin Decline: The gross margin for Q4 dropped to 12%, down from 35% in the previous year, illustrating the negative impact of reduced treatment volumes and a shift in revenue mix on profitability.
- Improved Net Loss: The net loss for Q4 was $631,000, an improvement from a net loss of $1.6 million in the same quarter last year, yet it still presents challenges for the company's recovery in profitability.
See More
